~" A non-ionic water-soluble contrast medium, Amipaque (metrizamide), was studied for use in ventriculography both experimentally and clinically, and identified as having markedly low toxicity. Twenty adult mongrel dogs were injected intraventricularly or intracisternally with 2.0 to 5.0 ml of Amipaque. It was found that Amipaque is safe compared with other water-soluble contrast media, especially relative to epileptogenic effect. The authors also carried out 17 clinical trials of ventriculography using 4.0 to 15.0 ml of Amipaque in 13 neurosurgical patients. There were no troublesome symptoms except for a mild headache as a side-effect in one patient, and Amipaque proved to be a satisfactory diagnostic contrast medium.
~ IPAQUE (metrizamide) is a new water-soluble contrast medium recently developed and made available commercially in Norway.* Unlike watersoluble contrast media previously in use, it is non-ionic and has been identified as exceptionally safe in many toxicity studies in northern and western Europe. 7 We have carried out animal experiments to confirm the usefulness of Amipaque in ventriculography, applied it clinically, and concluded that it is adequately safe in corn-*Amipaque is manufactured by Nyegaard and Co., Oslo, Norway.
parison with similar contrast media. The results of these studies are reported in this paper.
Animal Study

Material and Methods
We used 20 adult mongrel dogs weighing 4.0 to 10.5 kg (average 6.3 kg); all the dogs were anesthetized intravenously with 25 to 30 mg/kg of Nembutal (sodium pentobarbital) without any premedication. Amipaque was used as an isotonic solution (170 mg/ml), prepared by dissolving 6.75 gm in a vial with 16.1 ml of solvent (sodium bicarbonate solu- tion, 5 mg/ml), and administered in 1.5 to 5.0 ml dosages, injected through a tube inserted in the right lateral ventricle in 12 dogs, and by cisternal puncture in eight. The instruments and procedures of ventricular tap in dogs have previously been described? 1 V e n t r i c u l o g r a p h y , electroencephalography, and cerebrospinal fluid (CSF) studies were performed as shown in Table 1 . We observed all animals for somatic reaction, and carried out three histological studies for each, one at 24 hours and the other two a month after the injection. tElectroencephalography was performed for 2 hours postinjection, with silver electrodes set in four epidural sites.
Experimental Results
Ventriculography. A picture of the whole ventricular system was obtained by x-ray photography immediately after the injection of 2.0 ml of Amipaque through the tube inserted in the right lateral ventricle; this method gave about the same sharpness of definition as 60% Conray (meglumine iothalamate) or Dimer-X (meglumine iocarmate) (Fig. 1) .
Eleetroencephalography. Continuous EEG recordings were taken in six dogs before and for 2 hours after the injection of Amipaque; two received ventricular injections of 2.0 ml, one 2.5 ml, and another 3.0 ml; two dogs received cisternal injections of 3.0 ml. In five cases, no change was noted. One dog (weighing 7.1 kg) that received a 2.0-ml ventricular injection showed a slight increase of amplitude of the sharp wave that had already been present before the injection. This, however, was apparently different in form from those spikes evoked by other watersoluble contrast media. With Dimer-X, which was found to have the least epileptogenicity in our previous study, 11 we clearly noted occurrences of spikes in the EEG's of two of five dogs. One of these two was given 2.0 ml of Dimer-X and evidenced facial myoclonus; the other received 1.5 ml and showed no epileptic symptoms.
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Cerebrospinal Fluid Study. Cisternal injections of Amipaque were given to six dogs, five receiving 2.0 ml and one receiving 5.0 ml. Samples of CSF taken before and 24 hours after the injection were analyzed for cell count, protein, and sugar (Table 2 ). Cell count increased by 35/cu mm on the average, sugar tended to decline a little, and protein varied within the range considered normal. A control group of three dogs given cisternal injections of 2.0 ml of Dimer-X showed increased cell counts (24 hours after the injection) of 26/cu mm, 66/cu mm, and 38/cu mm, or an average of 43/cu mm.
Postinjection Symptoms. All the dogs were awakened promptly after anesthesia with no signs of localized myoclonus or general convulsion, and were able to stand the next day and take food. In this regard, Amipaque appears to be significantly safer than other media (Table 3) .
Histological Study. Specimens of the ventricular wall and choroid plexus were prepared from the three dogs sacrificed after the ventricular injection of 2.0 ml of Amipaque, one dog after 24 hours, and the other two 1 month after the injection. The specimens were stained with hematoxylin and e0sin. No abnormal finding was observed in these three cases (Fig. 2 ).
C l i n i c a l S t u d y
Clinical Material and Methods
Ventriculography with Amipaque was performed on 13 patients aged 6 to 74 years, on a total of 17 occasions (Table 4) . Amipaque of the lateral or the third ventricle, except for patients who had undergone shunt procedures; in the latter, Amipaque was injected by percutaneous puncture through a Braden's flushing reservoir, t In one patient with recurrent brain tumor the injection was made percutaneously from the site of external decompression; in a patient with posterior fossa arachnoiditis the injection was made by cisternal puncture. Ventriculography with the largest dosage in our series (15 ml) was performed on a 6-year-old boy who had previously been diagnosed by myelography as having a spinal cord tumor; his neurological signs and abnormal brain scintigrams both suggested the presence of brain tumor. The normal ventricular system and, as we in#Flushing reservoir manufactured by HeyerSchulte Corp., Santa Barbara, California. 
*Numbers in parenthesis indicate dogs receiving cisternal injections.
tended, the upper border of the spinal cord tumor, were revealed simultaneously.
In spite of its favorable diffusibility, since Amipaque tends to sink in CSF due to its greater density (1.184 gm/ml, 37 ~ C), the patient should be positioned so that the region to be visualized is lower than the tip of the cannula during the injection, as with other water-soluble contrast media.
Clinical Results
All of the ventriculograms and a cisternogram with Amipaque proved to be of adequate diagnostic value. Follow-up ventriculographic study after radiation therapy was easily carried out by percutaneous injection through the flushing reservoir (Fig. 3) . In cases of third ventriculography carried out at the time of stereotaxic operation, we usually injected 3 to 4 ml of air with contrast medium to delineate the anterior and posterior commissures (Fig. 4) .
One patient who was operatively diagnosed as having posterior fossa arachnoiditis complained of a mild headache, starting about 1 hour after completion of preoperative ventriculography with 9 ml of Amipaque; there Left." Before radiation therapy. Tumor in the third ventricle was well revealed by selective third ventriculography with Amipaque (4.0 ml). Right: After radiation therapy. Amipaque (10 ml) was injected through the Braden's flushing reservoir and the reduction of the tumor was confirmed.
were, however, no such effects in the other 12 cases.
E l e c t r o e n c e p h a l o g r a m s were recorded before A m i p a q u e injection and until 2 hours after the injection in two cases involving stereotaxic o p e r a t i o n s and in one case involving p i n e a l o m a . N o a b n o r m a l changes were found in any o f the three. In six patients C S F was a n a l y z e d before and 24 hours after the injection, but no significant change was observed in cell count, protein, or sugar (Table 5) .
Three o f 13 p a t i e n t s died, but in each case death o c c u r r e d as an inevitable outcome of the disease itself, and was not caused by A m i p a q u e . 
Discussion
The major problem of using water-soluble contrast media for ventriculography has been the epileptogenic effect, and research has been directed at minimizing this side-effect. With the advent of Amipaque we have made important progress toward this goal. This medium is non-ionic and characterized by the conformity of the osmotic pressure (0.300 mol/kg) of its isotonic solution with that of human blood (0.301 mol/kg). The adequacy of definition it provides is demonstrated by the ventriculograms we performed in dogs, and our comparison with other contrast media. This finding was also supported by additional clinical application.
To observe possible changes in the nature of CSF by the administration of Amipaque in the CSF space, a study was carried out both experimentally and clinically. In animal experiments, the injection of contrast medium and CSF sampling were carried out on all dogs by cisternal puncture to avoid the influence of blood flowing in from trephination or brain damage from ventricular tap. The result at 24 hours after the injection was an average increase of cell count by 35/cu mm, a tendency toward moderate decline of sugar, but almost no variation within the limits conside~'ed normal for protein. None of the clinical cases showed any outstanding changes. Amipaque was satisfactory also in similar studies of clinical cases, ',5,~2 and seems to be by no means inferior to 60% Conray, Dimer-X, or Methyodal. Likewise, we studied three dogs for possible changes in cell count of CSF 24 hours after an injection of Dimer-X; the resulting average cell count increase of 45/cu mm roughly agrees with results .obtained with Amipaque. A considerable increase in cell count after pneumoencephalography, however, has also been reported elsewhere? The influence of Amipaque on the CSF appeared to be negligible.
Regarding epileptogenicity, none of the 20 dogs subjected to the experiment with ventricular or cisternal injection of 1.5 to 5.0 ml of Amipaque showed either localized myoclonus or general convulsion. This finding supports the superior safety of this contrast medium; our previous experiment ~ with 1.5 to 2.0 ml of Dimer-X and 60% Conray resulted in epileptic symptoms. No clear spike was recorded in the EEG in six dogs treated with 2.0 to 3.0 ml of Amipaque, with one exception in which an increase in amplitude of the sharp wave, present before injection, was observed in a dog that received a ventricular injection of 2.0 ml. All dogs except this one had an uneventful course for at least 2 hours after the injection. Since all of the spikes that result with Angiografin (meglumine diatrizoate), 60% Conray, or Dimer-X occur within 60 minutes after the injection, our observations were also confined to 2 hours. However, Oftedal 8 reported in his similar experiment that four of eight spikes obtained in cats receiving 3.0 ml of Amipaque (a metrizamide solution containing 280 mg iodine/ml) occurred later than 2 hours; the delay of 2 hours therefore might not be adequate. Nevertheless, our EEG recording in three clinical cases for a 2-hour period indicates no irregularity at all with a 4-ml dose of Amipaque. No epileptic phenomena were observed in any of the 13 clinical cases. Skalpe and Amundsen 9 also reported no epileptic symptoms in 17 cases in their clinical experience, including patients receiving 10 ml of Amipaque.
According to Gonsette, 4 who performed EEG's in 46 cases with myelography and five cases with ventriculography, abnormal, nonirritative waves were detected in eight cases (16%), but these consisted substantially of slow waves. Other EEG studies have reported abnormalities with Amipaque, chiefly in cases of lumbar myelography, 5,6,12 but the irregularities observed were minor and tended to change to slow waves, which supports the contention that Amipaque is relatively nonepileptogenic.
The only other side-effect we encountered was mild headache in one patient among the 13 cases of ventriculography with Amipaque. Headache, vomiting, and dizziness have often been reported in association with myelography; 4,5,1~ however Skalpe and Amundsen ~ also reported a headache in one case and nausea in another as the only side-effects in 17 cases of ventriculography with Amipaque.
Finally, to clarify the influence of this medium on the tissue of the central nervous system a histological study was made of the ventricular wall and choroid plexus of three dogs. Two of the three dogs were sacrificed at 1 month and the other 24 hours after injection of 2.0 ml of Amipaque. No pathological change was found.
Some reports x,2 state that traditional water-soluble contrast media cause relatively high incidences of adhesive arachnoiditis. Long-term observation after the administration of the medium seems to be necessary, but it is our impression that the superiority of this medium in terms of safety is such that our concept of water-soluble contrast media has largely been changed.
